Nalaganje...
Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
As patients with non-small cell lung cancer (NSCLC) and wild-type epidermal growth factor receptor (EGFR) are resistant to treatment with erlotinib or gefitinib, potential chemosensitizers are required to potentiate wild-type EGFR NSCLC cells to erlotinib/gefitinib treatment. The present study repor...
Shranjeno v:
| izdano v: | Mol Med Rep |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
D.A. Spandidos
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6131653/ https://ncbi.nlm.nih.gov/pubmed/30106133 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2018.9347 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|